Acyclic nucleoside phosphonates have been prepared in a straightforward manner and in high yields by an enantioselective palladium-catalyzed allylic substitution involving nucleic bases as nucleophiles followed by cross-metathesis reaction with diethyl allylphosphonate.
Introduction
Acyclic nucleoside phosphonates (ANPs) 1 belong to a family of modified nucleoside analogues, in which the sugar moiety has been replaced by a functionalized acyclic chain linking the nucleobase at one end and the phosphonic acid group at the other. Relevant ANPs that have been pursued as antiviral agents are cidofovir (HPMPC), adefovir (PMEA), and tenofovir 2 (PMPA) (Fig. 1 ). Because of their limited oral bioavailability, the last two compounds have been converted to their oral prodrug forms, adefovir dipivoxil or bis( pivaloyloxymethyl)-
PMEA [bis(POM)-PMEA] and tenofovir disoproxil or bis(isopropyloxycarbonyloxymethyl)-PMPA [bis(POC)-PMPA]
, respectively. Many analogues of these compounds have been prepared incorporating modifications in the base, alkyl chain or in the phosphonate moiety. Examples of modification in the alkyl chain are vinyl and allyl ANPs, where a CH 2 group replaces the oxygen of the ether function in the alkyl chain ( Fig. 1 ).
3
Acyclic nucleosides are commonly synthesized from nucleic bases and chiral starting materials by alkylation, Mitsunobu reaction, epoxide opening, 4 and by silver-catalyzed addition of different nucleophiles to 9-allenyl-9H-purines. 5 The reported asymmetric synthesis of acyclic nucleosides involves the transition metal- 6 or organocatalyzed 7 aza-Michael reaction of purinic bases to acrylates and asymmetric hydrogenation of purine-substituted acrylates.
2 Allylic substitution has also been used in the synthesis of acyclic nucleosides to provide compounds with the nucleic base linked to the terminal carbon. 8 Hartwig recently reported an enantioselective allylic amination using an iridium catalyst to afford acyclic nucleosides where the nucleic base is bonded to a stereocenter. 9 Trost described the desymmetrization of meso 1,4-cyclopentenyl-dibenzoate derivatives using palladium-DACH catalysts in a straightforward synthesis of carbocyclic nucleosides. 10 He found that the use of nucleobases as nucleophiles has a remarkable effect on the catalytic turnover and the enantioselectivity of desymmetrization reactions. 9 Furthermore, Pd-catalyzed DYKAT of vinyl epoxide 4 is an efficient procedure for preparing 2-amino-3-buten-1-ol derivatives, 11 which are attractive intermediates for synthesizing acyclic nucleosides, although for this purpose it will be necessary to explore the behavior of the different nucleic bases in the reaction. Recently, we have demonstrated that allyl carbonate 5, substituted with a hydroxymethyl group, is an appropriate substrate for the Pd-catalyzed asymmetric allylic amination reaction (Pd-AAA), affording the branched derivative with high similar conditions using epoxide 4 and di-Boc-cytosine (6a), branched product 7a was obtained in 81% yield and 62% ee (Table 1 , entry 1). Decreasing the temperature to 0°C did not practically improve the enantioselectivity, while conducting the reaction at 35°C eroded the enantioselectivity significantly (Table 1 , entries 2 and 3). The analogous reaction of carbonate 5 with di-Boc-cytosine (6a) using the (S,S) ligand (Table 1 , entry 4) furnished the enantiomer ent-7a in 92% yield and 73% ee. Interesting enough, all reactions from both 4 and 5 were highly regioselective affording exclusively the branched isomer. The use of BSA-KOAc did not improve the results. Lowering the temperature to 0°C did not improve the enantioselectivity (Table 1, entry 5) . Further optimization was focused on the precatalyst loading: a reduction from 2 mol% to 1 mol% produced a drastic decrease in the enantioselectivity (Table 1, entry 6) , while an increase in the precatalyst loading to 3 mol% did not provide significant improvement (result not shown in the table). In this context, we selected room temperature and 2 mol% of the palladium precursor as standard reaction conditions. It can be concluded from Table 1 that, in analogy to reaction from vinyl epoxide 4, Pd-AAA from carbonate 5 with diBoc-cytosine (6a) using the [Pd(η 3 -C 3 H 5 )Cl] 2 /DACH-naphthyl ligand as the catalytic system provides good yields of the branched aminated product 7a/ent-7a in complete regioselectivity and moderate enantioselectivity. We therefore decided to extend this comparative study to other purinic bases. The results are collected in Table 2 . Di-Boc-adenosine (6b) reacted with epoxide 4 in the presence of the (R,R)-DACH-naphthyl ligand to provide 7b in an excellent yield of 92% and 92% ee (entry 2). When the reaction was conducted with carbonate 5 using the (S,S)-DACHnaphthyl ligand, ent-7b was obtained in an excellent yield of 92% and 88% ee (entry 2).
6-Chloropurine (6c) is a versatile starting material in nucleoside synthesis since it allows a set of useful and wellknown transformations for the synthesis of nucleoside derivatives. When carbonate 5 was treated with 6c in the presence of the (S,S)-DACH-naphthyl ligand under the standard conditions, compound ent-7c was obtained in very good 91% enantioselectivity, slightly higher than that obtained from 6b (Table 2 , entry 2 vs. 4). Pd-AAA of 6c from epoxide 4 furnished the allylated purine ent-7c with almost the same enantioselectivity of that obtained from 6b (Table 2 , entry 1 vs. 3). e The absolute configurations of the products were established by analogy with those obtained by Trost using phthalimide as analogous soft N-nucleophiles to nucleic bases (ref. 11a) .
f The (R,R)-naphthyl ligand was used.
g The (S,S)-naphthyl ligand was used. h 1 mol% [Pd(η Furthermore, the reaction of epoxide 4 and carbonate 5 with benzimidazole (6d) as a nucleophile using the (S,S)-DACH-naphthyl ligand, afforded compound ent-7d in good yields and the same enantioselectivity, (88% ee) ( Table 2 , entries 5 and 6).
Di-Boc-2-amino-6-chloropurine 6e reacted with epoxide 4 and carbonate 5 under standard conditions to provide 7e with high enantioselectivity but with low to moderate yields (Table 2, entries 7 and 9). However, on inverting the reaction stoichiometry a substantial improvement in the yield was achieved (64%) with the same enantio-induction (Table 2, entry 8).
Contrary to their complementary behavior in terms of regioselectivity observed with hard amine nucleophiles, 12 both epoxide 4 and carbonate 5 afforded valuable branched products with high degrees of enantioselectivity when reacting with nucleobases. The regioselectivity observed in the reactions of epoxide 4 with nucleobases is comparable to that already observed with other soft nitrogen nucleophiles, such as imides or imidocarboxylates, as a result of a dynamic kinetic asymmetric transformation. As for carbonate 5, the branched regioisomer is always observed as a major product, regardless of the nitrogen nucleophile used, due to an enantioselective Pd-allylic amination, where hydrogen bonding interactions play an important role both in the ionization and the nucleophilic attack steps.
12
Having explored the feasibility of using nucleic bases as nucleophiles for the synthesis of chiral branched heterocycles via a Pd-AAA with the DACH-naphthyl Trost ligand, we selected compounds 7a, 7b and 7e for synthesizing model acyclic pyrimidine and purine nucleosides.
For this purpose, the primary hydroxyl group was initially protected by reaction with tert-butyldiphenylsilyl chloride in DMF in the presence of imidazole to afford compounds 8a,b,e in excellent yields (Scheme 2). According to the retrosynthetic scheme and following previous studies in the field, 14 compounds 8a,b were then treated with diethyl allylphosphonate 15, 16 in the presence of Grubb-Nolan's catalyst to afford compounds 9a,b in excellent 92% and 90% yields, respectively, as a result of a cross-metathesis reaction. The reaction of 8e under similar conditions afforded 9e in a moderate 52% yield. Compounds with E configuration were exclusively obtained. Removal of the protecting groups 15 in the nucleic base, the phosphonate moiety and the hydroxyl group, was carried out by treatment of compounds 9a,b with TMSBr 15 in dichloromethane to afford the target acyclic nucleosides 1 and 2 in excellent yields. Additionally, compound 9e was treated under the deprotection conditions to afford the 2-amino-6-chloro-9H-purine derivative 10 in good yield. The saturated nucleoside 11, with an increased conformational mobility, was prepared by the reduction of the double bond in 9a (Scheme 3). Attempts to reduce the double bond under 1 bar of hydrogen pressure and using palladium on charcoal 17 as catalysts led to no conversion. At higher hydrogen pressure (10 bar) the presence of two products was observed by 1 H NMR, corresponding to the expected Scheme 2 compound 11 and to a secondary product resulting from the reduction of the double bond and partial reduction of the cytosine. Optimal conditions were found driving the reaction at room temperature and using 3 bar of hydrogen pressure. In this way, full conversion and 87% yield of compound 11 was obtained. Removal of protecting groups using TMSBr afforded acyclic nucleoside phosphonate 12 in 80% yield.
In conclusion, acyclic nucleosides 1, 2, 10 and 12 were successfully prepared in high yields by palladium-catalyzed allylic amination from compounds 4 and 5, using pyrimidinic and purinic bases as nucleophiles, followed by rutheniumcatalyzed cross-metathesis with diethyl allylphosphonate and removal of protecting groups. Excellent enantioselectivity was obtained for the purinic derivatives 2 and 10.
Experimental section

General methods
All chemicals used were reagent grade and used as supplied unless otherwise specified. HPLC grade dichloromethane (CH 2 Cl 2 ), tetrahydrofuran (THF) and dimethylformamide (DMF) were dried using a solvent purification system (PureSolv 400). Toluene was purified using standard procedures. (4) (1.0 eq.) was then added in one portion. The mixture was stirred at room temperature for 18 h. The reaction mixture was then diluted with H 2 O. The phases were separated and the aqueous phase was extracted with CH 2 Cl 2 . The combined organic phases were dried over MgSO 4 , filtered, and concentrated under vacuum. The resulting crude was purified by flash chromatography to afford a pure product. General procedure 2. Palladium-catalyzed allylic amination from (E)-4-hydroxybut-2-en-1-yl methyl carbonate (5) . In a Schlenk tube, [Pd(η 3 -C 3 H 5 )Cl] 2 (2 mol%), the (S,S)-DACHnaphthyl ligand (6 mol%) and CH 2 Cl 2 (c = 0.02 M) were introduced under an argon atmosphere. The resulting mixture was stirred for 20 minutes. Carbonate 5 (1.0 eq.) and nucleophile (1.1 eq.) were then successively introduced. The mixture was stirred at room temperature for 18 h. The reaction mixture was then diluted with H 2 O. The phases were separated and the aqueous phase was extracted with CH 2 Cl 2 . The combined organic phases were dried over MgSO 4 , filtered, and concentrated under vacuum. The resulting crude was purified by flash chromatography to afford a pure product. 9, 155.8, 149.7, 147.2, 147.0, 132.7, 120.5, 96.2, 85.1, 62.7, 61.2, 27. (R)-6-Chloro-9-(1-hydroxybut-3-en-2-yl)-9H-purine (ent-7c). Following the general procedure 1, compound ent-7c was prepared from butadiene monoepoxide (4) , J = 7.7 Hz), 7.36 (d, 1H, J = 7.7 Hz), 7.21 (t, 1H, J = 7.7 Hz), 7.14 (t, 1H, J = 7.7 Hz), 6.11 (ddd, 1H, J = 17.0, 10.8, 5. C NMR (CDCl 3 , 100.6 MHz,): δ (ppm) 152.2, 151. 5, 151.3, 150.4, 146.0, 132.2, 129.9, 120.0, 83.9, 63.4, 60.9, 27.8 
S)-N,N-Bis(tert-butoxycarbonyl)-1-[1-(tert-butyldiphenyl-silyloxy) but-3-en-2-yl]cytosine (8a).
Compound 7a (100 mg, 0.26 mmol) was dissolved in dry DMF (3 mL), treated under argon with tert-butyldiphenylchlorosilane (0.08 mL, 0.3 mmol) and imidazole (40 mg, 0.6 mmol), and the reaction mixture was stirred for 16 h at room temperature. The solution was then diluted with water and extracted with Et 2 O, and the organic layer was dried and evaporated. The residue was purified by column chromatography on silica gel (hexanes/EtOAc 10 : 2) to provide 137 mg (85%) of compound 8a. , 2857, 1742, 1671, 1524, 1455, 1370, 1319, 1256, 1137, 1110, 784, 701 . 13 C NMR (CDCl 3 , 100.6 MHz): δ ( ppm) 161. 9, 155.0, 149.8, 147.1, 135.7, 135.5, 133, 132.6, 130.1, 128.0, 120.6, 95.6, 84.9, 63.9, 59.6, 27.9, 26.7, 19. (S)-N,N-Bis(tert-butoxycarbonyl)-9-[1-(tert-butyldiphenylsilyloxy) but-3-en-2-yl]adenine (8b). Compound 7b (250 mg, 0.6 mmol) was dissolved in dry DMF (7 mL) and treated under argon with tert-butyldiphenylchlorosilane (0.18 mL, 0.66 mmol) and imidazole (90 mg, 1.32 mmol), and the mixture was then stirred for 16 h at room temperature. The solution was then diluted with water and extracted with Et 2 O, and the organic layer was dried and evaporated. The residue was purified by column chromatography on silica gel (hexanes/EtOAc 10 : 2) to provide 319 mg (80%) of compound 8b as a colourless oil. [α] − 10.93 (c 1.13, CHCl 3 ) . FTIR-ATR (cm −1 ): 2987, 2362, 1733, 1716, 1558, 1540, 1507, 1456, 1395, 1259, 1066, 749 153.3, 151.8, 150.5, 150.3, 144.5, 135.5, 135.4, 132.5, 130.1, 128.9, 127.9, 119.8, 83.7, 64.8, 59.4, 27.9, 26.8, 19 (S)-2-Bis-tert-butoxycarbonyl-amino-6-chloro-9-[1-(tert-butyl diphenylsilyloxy)-but-3-en-2-yl]-9H-purine (8e). Compound 7e (113 mg, 0.257 mmol) was dissolved in dry DMF (3 mL) and treated under argon with tert-butyldiphenylchlorosilane (80.1 μL, 0.308 mmol) and imidazole (40 mg, 0.59 mmol), and the mixture was then stirred for 16 h at room temperature. The solution was then diluted with water and extracted with Et 2 O, and the organic layer was dried and evaporated. The residue was purified by column chromatography on silica gel (hexanes/EtOAc 10 : 2) to provide 244 mg (95%) of compound 8e as a colourless oil. 4, 151.7, 150.9, 150.4, 145.7, 135.5, 135.3, 132.3, 132.2, 132.1, 130.1, 130.0, 129.7, 127.9, 119.9, 83.4, 64.7, 59.2, 27.8, 26.7, 19 
To a solution of product 8a (50 mg, 0.08 mmol) and II generation Grubbs catalyst (4 mg, 0.004 mmol) in dichloromethane (4 mL) was added diethylallylphosphonate (0.06 mL, 0.32 mmol) and the reaction mixture was heated to reflux for 16 h. The solvent was then evaporated and the reaction crude was purified by silica gel chromatography (hexanes/EtOAc 1 : 2) to provide 57 mg (92%) of compound 9a as a yellow liquid. 7, 154.6, 149.5, 146.9, 135.5, 135.3, 132.5, 132.4, 130, 129.9, 129.5, 129.4, 128.5, 127.8, 126.5, 126.3, 95.4, 84.7, 63.6, 62, 59.4, 30.6 ( J = 140 Hz) 27.7, 26.8, 19.1, 
To a solution of product 8b (140 mg, 0.22 mmol) and II generation Grubbs catalyst (9 mg, 0.011 mmol) in dichloromethane (11 mL) was added diethylallylphosphonate (0.16 mL, 0.88 mmol) and the reaction mixture was heated to reflux for 16 h. The solvent was then evaporated and the reaction crude was purified by silica gel chromatography (hexanes/EtOAc 2 : 1) to provide 157 mg (90%) of product 9b as a green liquid. [α] 25 D −14.6 (c 1.36, CHCl 3 ). FTIR-ATR (cm −1 ): 2929, 2856, 1788, 1599, 1452, 1369, 1252, 1139, 1111, 1026, 704 . 1 H NMR (CDCl 3 , 400 MHz): δ ( ppm) 8.77 (s, 1H), 8.20 (s, 1H), 10H), 1H), 5.76 (ddd, 1H, J = 15.6, 10.4, 7.6 Hz), 5.25 (brs, 1H), 4.16 (dd, 2H, J = 10.4, 6.4 Hz), 4H) , 2.56 (dd, 1H, J = 21.0, 7.6 Hz), 1.43 (s, 18H), 1.22 (t, 6H, J = 6.8 Hz), 0.93 (s, 9H). 13 C NMR (CDCl 3 , 100.6 MHz): δ ( ppm) 153.2, 151.9, 150.6, 150.4, 144.5, 135.2, 132.4, 130.1, 129.1, 129.0, 128.0, 126.2, 83.8, 64.8, 62.2, 62.1, 59.2, 30.6 ( J = 140 Hz), 28.0, 26.9, 19.2, 16.6 Diethyl (2E,4S) 2-bis-tert-butoxycarbonyl-amino-6-chloro-9-[1-(tert-butyl-diphenylsilyloxy)-5-phosphonopent-3-en-2-yl]-9H-purine (9e). To a solution of product 8e (134 mg, 0.197 mmol) and II generation Grubbs catalyst (8 mg, 0.009 mmol) in dichloromethane (8 mL) was added diethylallylphosphonate (0.134 mL, 0.788 mmol) and the reaction mixture was heated to reflux for 16 h. The solvent was then evaporated and the reaction crude was purified by silica gel chromatography (hexanes/EtOAc 1 : 2) to provide 86 mg (52%) of compound 9e as a colourless oil. 1, 151.6, 150.9, 150.5, 145.5, 135.4, 135.3, 132.1, 130.1, 130.0, 129.8, 128.6, 128.5, 127.9, 127.8, 126.5, 126.4, 83.5, 64.7, 62.1, 61.9, 58.7, 31.2, 29.8, 27.9, 26.7, 19.0, 16.5, 16.4, (2E,4S)-1-[5-Phosphono-1-hydroxypent-3-en-2-yl]cytosine (1). TMSBr (0.08 mL, 0.6 mmol) was added to a solution of compound 9a (80 mg, 0.10 mmol) in CH 2 Cl 2 (7 mL), and the mixture was stirred for 60 h at room temperature under positive pressure of dry Ar. The reaction was quenched by adding MeOH (3 mL) and the reaction mixture was then evaporated by heating at 60°C. This process was repeated three times. 8, 149.0, 147.0, 127.5, 127.4, 94.6, 60.9, 59.8, 31.8 (d, J = 130 Hz 6, 148.3, 143.9, 143.6, 127.8, 127.6, 118.1, 62.3, 59.2, 32.4 (d, J = 130 Hz) . HRMS (ESI-TOF) m/z: [M + Na] + calcd for C 10 H 15 N 5 NaO 4 P 323.0759, found 323.0769. (2E,4S)-2-Amino-6-chloro-9-(5-phosphono-1-hydroxypent-3-en-2-yl)-9H-purine (10). TMSBr (0.75 mL, 0.572 mmol) was added to a solution of compound 9e (79 mg, 0.095 mmol) in CH 2 Cl 2 (7 mL), and the mixture was stirred for 60 h at room temperature under positive pressure of dry Ar. The reaction was quenched by adding MeOH (3 mL) and the reaction mixture was then evaporated by heating at 60°C. This process was repeated three times. The resulting residue was extracted with H 2 O and CH 2 Cl 2 , and the aqueous phase was evaporated to dryness to afford compound 10 (19 mg, 60%) as a brown oil. 9, 137.5, 136.7, 135.6, 128.0, 107.7, 61.8, 60.9 (m) 4.80 (brs, 1H), 4.12-3.93 (m, 4H) , 3.84 (dd, 1H, J = 3.6, 11.2 Hz), 3.80 (dd, 1H, J = 3.2, 11.2 Hz), 1.95-1.86 (m, 2H), 1.77-1.63 (m, 4H), 1.55 (s, 18H), 1.26 (t, 6H, J = 6.8 Hz), 1.01 (s, 9H). 13 C NMR (CDCl 3 , 100.6 MHz): δ ( ppm) 161.8, 155.3, 149.8, 146.2, 135.7, 132.7, 130.2, 128.0, 95.7, 85, 64.4, 61.8, 61.7, 29.8, 27.9, 26.5 ( J = 140 Hz), 24.5, 19.3, 16.7, 16.6 (12) . TMSBr (0.15 ml, 0.9 mmol) was added to a solution of compound 11 (120 mg, 0.15 mmol) in CH 2 Cl 2 (12 mL) and the mixture was stirred for 60 h at room temperature under positive argon pressure. Then MeOH (3 mL) was added and evaporated with heating (ca. 60°C). This process was repeated three times. 
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